ClinicalTrials.gg
TerminatedNCT02405442Updated Apr 23, 2019Results posted

Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

A Phase 2 interventional study of Andecaliximab and Placebo in Crohn's Disease, sponsored by Gilead Sciences. Terminated at 74 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-04-23.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Enrollment
139th of 528
187 · median 60
Started
2015
with 29 others
Phase 2
141 of 660
23 open now
Registered
282nd of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 139th largest by enrollment of the 528 interventional ones that give a count, is one of 30 that started in 2015, is one of 141 in phase 2, and was the 282nd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

This study will primarily evaluate the safety and efficacy of andecaliximab in adults with active Crohn's disease. The study will consist of a Double-Blind Phase of 8 weeks followed by an Open-Label Extension. Participants who complete the Double-Blind Phase will be eligible to enroll in the optional Open-Label Extension for an additional 44 weeks. Participants who complete Week 52 assessments will be eligible to enter the Extended Treatment Phase to continue treatment with andecaliximab for an additional 156 weeks.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ability to provide a written
  • Females of must have a negative pregnancy test at screening and baseline
  • Documented diagnosis of Crohn's disease with a minimum disease duration of 6 months with involvement of the ileum and/or colon at a minimum
  • Moderately to severely active Crohn's disease as defined by a Crohn's Disease Activity Index (CDAI) total score between 220-450 (inclusive) AND with evidence of active disease as measured by ileocolonoscopy
  • Within the previous 5 years, demonstrated an inadequate clinical response or intolerance of at least one of the following agents:

    • Immunomodulators
    • Tumor necrosis factor-alpha (TNFα) antagonists
    • Vedolizumab
  • May be receiving the following drugs:

    • Oral 5-aminosalicylate (5-ASA)
    • Oral corticosteroid therapy
    • Antidiarrheals for chronic diarrhea
    • Azathioprine or 6-mercaptopurine (6-MP) or methotrexate
    • Antibiotics for the treatment of Crohn's disease
  • Able to comply with the dosing instructions for study drug and able to comply with the study visits and requirements

Key Exclusion Criteria:

  • Evidence of abscess at screening
  • Extensive colonic resection (subtotal or total colectomy) or history of > 2 small bowel resections
  • Ileostomy, colostomy, or symptomatic stenosis of the intestine
  • Current use of oral corticosteroids at a dose equivalent to > 30 mg/day of prednisone
  • Ulcerative colitis or indeterminate colitis
  • Short bowel syndrome
  • Stool sample positive for Clostridium difficile (C. difficile) toxin, E. coli, Salmonella, Shigella, Campylobacter or Yersinia
  • Treatment with any monoclonal antibody within 4 weeks of screening
  • History or evidence of colonic mucosal dysplasia
  • , , , or tuberculosis (TB) infection
  • Participated in a clinical study with an drug or biologic within the last 30 days
  • Any chronic medical condition (including, but not limited to, cardiac or pulmonary disease) that, in the opinion of the investigator, would make the individual unsuitable for the study or would prevent compliance with the study protocol

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    Andecaliximab 150 mg Every 2 Weeks

    Double-Blind Phase: Participants will receive 1 single-use prefilled syringe (PFS) of andecaliximab 150 mg and matching placebo coadministered at Weeks 0, 2, 4, and 6 and 2 single-use PFS of placebo coadministered at Weeks 1, 3, 5, and 7. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.

    Drug: Andecaliximab · Drug: Placebo

  • Experimental
    Andecaliximab 150 mg Weekly

    Double-Blind Phase: Participants will receive 1 single-use PFS of andecaliximab 150 mg and matching placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.

    Drug: Andecaliximab · Drug: Placebo

  • Experimental
    Andecaliximab 300 mg Weekly

    Double-Blind Phase: Participants will receive 2 single-use PFS of andecaliximab 150 mg coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.

    Drug: Andecaliximab

  • Placebo comparator
    Placebo

    Double-Blind Phase: Participants will receive 2 single-use PFS of placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.

    Drug: Andecaliximab · Drug: Placebo

Interventions

  • Andecaliximab administered via subcutaneous (SC) injection

    Also known as: GS-5745

  • DrugPlacebo

    Placebo to match andecaliximab administered via SC injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Response (PRO2 Score ≤ 8) at Week 8 of the Double-Blind Phase

    Clinical response was defined as patient-reported outcomes (PRO2) score ≤ 8 at Week 8. PRO2 is the weighted average of the 2 variables of frequency of liquid or very soft stool and abdominal pain, based on 7-day participant diary data. The PRO2 score has a minimum score of 0 and has no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with a missing PRO2 value at the Week 8 analysis visit were imputed as not achieving the Clinical Response.

    Time frame: Week 8

  2. Percentage of Participants Achieving Endoscopic Response (≥ 50% Reduction From Baseline SES-CD) at Week 8 of the Double-Blind Phase

    Endoscopic response was defined as ≥ 50% reduction from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 8. The SES-CD evaluates 4 endoscopic variables: ulcer size, ulcerated surface, affected surface, and presence of narrowings. The total SES-CD is calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with missing SES-CD value at Week 8 analysis visit were imputed as not achieving Endoscopic Response.

    Time frame: Week 8

Secondary outcomes

  1. Percentage of Participants Achieving CDAI Remission (CDAI ≤ 150) at Week 8 of the Double-Blind Phase

    Clinical remission was defined as Crohn's Disease Activity Index (CDAI) ≤ 150 at Week 8. CDAI is used as a measure of clinical response and remission. It includes 8 variables of patient-reported symptoms and objective variables: stool count, abdominal pain, general well-being, complications, use of anti-diarrheal medications, presence of abdominal mass, hematocrit values, and weight. It has a minimum range of 0 and no upper bound, with higher scores indicating greater disease activity. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with missing CDAI score at Week 8 analysis visit were imputed as not achieving CDAI Remission.

    Time frame: Week 8

  2. Percentage of Participants Achieving Mucosal Healing (SES-CD Size-of-Ulcer Subscore = 0) at Week 8 of the Double-Blind Phase

    The SES-CD evaluates 4 endoscopic variables: ulcer size, ulcerated surface, affected surface, and presence of narrowings. The SES-CD size-of-ulcer subscore ranges from 0 (none) to 3 (very large). Mucosal healing at Week 8 was defined as the size-of-ulcer subscore for segments with non-zero baseline value changes to zero at Week 8 AND the size-of-ulcer subscore for segments with zero value at baseline remain zero at Week 8. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with missing SES-CD size-of-ulcer subscore at Week 8 analysis visit were imputed as not achieving Mucosal Healing.

    Time frame: Week 8

07

Results

Posted Mar 28, 2019
Limitations and caveats
A prespecified topline analysis was performed after the last enrolled subject received the 8-week Double-Blind induction treatment. Based on this review, Gilead terminated the Open-Label and Extended Treatment Phases of study due to lack of efficacy.

Participant flow

Participants were enrolled at study sites in North America, Europe, South Africa, and Asia Pacific. The first participant was screened on 30 April 2015. The last study visit occurred on 22 December 2016.

Double-Blind Phase (up to Week 8)
Participant flow — Double-Blind Phase (up to Week 8)
MilestoneAndecaliximab 150 mg Every 2 WeeksAndecaliximab 150 mg WeeklyAndecaliximab 300 mg WeeklyPlacebo
Started53535328
Completed52484727
Not completed1561
Withdrew: Adverse event0241
Withdrew: Withdrew consent0120
Withdrew: Study disease-related symptoms1100
Withdrew: Investigator's discretion0100
Open-Label Phase (up to Week 52)
Participant flow — Open-Label Phase (up to Week 52)
MilestoneAndecaliximab 150 mg Every 2 WeeksAndecaliximab 150 mg WeeklyAndecaliximab 300 mg WeeklyPlacebo
Started52484726
Completed4322
Not completed48454524
Withdrew: Study terminated by sponsor27282813
Withdrew: Investigator's discretion1411112
Withdrew: Adverse event6126
Withdrew: Study disease-related symptoms0132
Withdrew: Withdrew consent1211
Withdrew: Lack of efficacy0100
Withdrew: Lost to follow-up0100
Extended Treatment Phase(up to Week 208)
Participant flow — Extended Treatment Phase(up to Week 208)
MilestoneAndecaliximab 150 mg Every 2 WeeksAndecaliximab 150 mg WeeklyAndecaliximab 300 mg WeeklyPlacebo
Started3222
Completed0000
Not completed3222
Withdrew: Study terminated by sponsor2122
Withdrew: Investigator's discretion0100
Withdrew: Study disease-related symptoms1000

Outcome measures

PrimaryPercentage of Participants Achieving Clinical Response (PRO2 Score ≤ 8) at Week 8 of the Double-Blind Phase

Clinical response was defined as patient-reported outcomes (PRO2) score ≤ 8 at Week 8. PRO2 is the weighted average of the 2 variables of frequency of liquid or very soft stool and abdominal pain, based on 7-day participant diary data. The PRO2 score has a minimum score of 0 and has no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with a missing PRO2 value at the Week 8 analysis visit were imputed as not achieving the Clinical Response.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response (PRO2 Score ≤ 8) at Week 8 of the Double-Blind Phase
percentage of participantsAndecaliximab 150 mg Every 2 WeeksAndecaliximab 150 mg WeeklyAndecaliximab 300 mg WeeklyPlacebo
Percentage of Participants Achieving Clinical Response (PRO2 Score ≤ 8) at Week 8 of the Double-Blind Phase17.0 (8.1 to 29.8)13.2 (5.5 to 25.3)11.3 (4.3 to 23.0)14.3 (4.0 to 32.7)
PrimaryPercentage of Participants Achieving Endoscopic Response (≥ 50% Reduction From Baseline SES-CD) at Week 8 of the Double-Blind Phase

Endoscopic response was defined as ≥ 50% reduction from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) at Week 8. The SES-CD evaluates 4 endoscopic variables: ulcer size, ulcerated surface, affected surface, and presence of narrowings. The total SES-CD is calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with missing SES-CD value at Week 8 analysis visit were imputed as not achieving Endoscopic Response.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Endoscopic Response (≥ 50% Reduction From Baseline SES-CD) at Week 8 of the Double-Blind Phase
percentage of participantsAndecaliximab 150 mg Every 2 WeeksAndecaliximab 150 mg WeeklyAndecaliximab 300 mg WeeklyPlacebo
Percentage of Participants Achieving Endoscopic Response (≥ 50% Reduction From Baseline SES-CD) at Week 8 of the Double-Blind Phase11.3 (4.3 to 23.0)13.2 (5.5 to 25.3)7.5 (2.1 to 18.2)10.7 (2.3 to 28.2)
SecondaryPercentage of Participants Achieving CDAI Remission (CDAI ≤ 150) at Week 8 of the Double-Blind Phase

Clinical remission was defined as Crohn's Disease Activity Index (CDAI) ≤ 150 at Week 8. CDAI is used as a measure of clinical response and remission. It includes 8 variables of patient-reported symptoms and objective variables: stool count, abdominal pain, general well-being, complications, use of anti-diarrheal medications, presence of abdominal mass, hematocrit values, and weight. It has a minimum range of 0 and no upper bound, with higher scores indicating greater disease activity. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with missing CDAI score at Week 8 analysis visit were imputed as not achieving CDAI Remission.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving CDAI Remission (CDAI ≤ 150) at Week 8 of the Double-Blind Phase
percentage of participantsAndecaliximab 150 mg Every 2 WeeksAndecaliximab 150 mg WeeklyAndecaliximab 300 mg WeeklyPlacebo
Percentage of Participants Achieving CDAI Remission (CDAI ≤ 150) at Week 8 of the Double-Blind Phase20.8 (10.8 to 34.1)17.0 (8.1 to 29.8)11.3 (4.3 to 23.0)21.4 (8.3 to 41.0)
SecondaryPercentage of Participants Achieving Mucosal Healing (SES-CD Size-of-Ulcer Subscore = 0) at Week 8 of the Double-Blind Phase

The SES-CD evaluates 4 endoscopic variables: ulcer size, ulcerated surface, affected surface, and presence of narrowings. The SES-CD size-of-ulcer subscore ranges from 0 (none) to 3 (very large). Mucosal healing at Week 8 was defined as the size-of-ulcer subscore for segments with non-zero baseline value changes to zero at Week 8 AND the size-of-ulcer subscore for segments with zero value at baseline remain zero at Week 8. Week 8 refers to the analysis window of Day 43 to Day 70 and prior to the first Open-Label dose date. Participants with missing SES-CD size-of-ulcer subscore at Week 8 analysis visit were imputed as not achieving Mucosal Healing.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Mucosal Healing (SES-CD Size-of-Ulcer Subscore = 0) at Week 8 of the Double-Blind Phase
percentage of participantsAndecaliximab 150 mg Every 2 WeeksAndecaliximab 150 mg WeeklyAndecaliximab 300 mg WeeklyPlacebo
Percentage of Participants Achieving Mucosal Healing (SES-CD Size-of-Ulcer Subscore = 0) at Week 8 of the Double-Blind Phase5.7 (1.2 to 15.7)1.9 (0.0 to 10.1)1.9 (0.0 to 10.1)7.1 (0.9 to 23.5)

Adverse events

Collected over Double-Blind Phase: First dose of andecaliximab to Week 8; Open-Label Phase (includes adverse events occurring in the Extended Treatment Phase): First dose of open label andecaliximab to the last dose date (maximum: 200 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Andecaliximab 150 mg Every 2 Weeks (Q2W)0/53 (0%)1/53 (1.9%)15/53 (28.3%)
Double-Blind Andecaliximab 150 mg Weekly (QW)0/53 (0%)6/53 (11.3%)25/53 (47.2%)
Double-Blind Andecaliximab 300 mg Weekly0/53 (0%)8/53 (15.1%)25/53 (47.2%)
Double-Blind Placebo0/28 (0%)3/28 (10.7%)13/28 (46.4%)
Open-Label Andecaliximab QW From Andecaliximab 150 mg Q2W0/52 (0%)9/52 (17.3%)22/52 (42.3%)
Open-Label Andecaliximab QW From Andecaliximab 150 mg QW0/48 (0%)10/48 (20.8%)21/48 (43.8%)
Open-Label Andecaliximab QW From Andecaliximab 300 mg QW0/47 (0%)7/47 (14.9%)17/47 (36.2%)
Open-Label Andecaliximab QW From Placebo0/26 (0%)6/26 (23.1%)16/26 (61.5%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventDouble-Blind Andecaliximab 150 mg Every 2 Weeks (Q2W)Double-Blind Andecaliximab 150 mg Weekly (QW)Double-Blind Andecaliximab 300 mg WeeklyDouble-Blind PlaceboOpen-Label Andecaliximab QW From Andecaliximab 150 mg Q2WOpen-Label Andecaliximab QW From Andecaliximab 150 mg QWOpen-Label Andecaliximab QW From Andecaliximab 300 mg QWOpen-Label Andecaliximab QW From Placebo
Crohn's diseaseGastrointestinal disorders0/533/532/530/284/525/484/473/26
Small intestinal obstructionGastrointestinal disorders0/530/530/530/282/521/482/470/26
AnaemiaBlood and lymphatic system disorders0/531/531/530/280/520/480/471/26
AppendicitisInfections and infestations0/530/530/530/280/520/480/471/26
Bacterial pyelonephritisInfections and infestations0/530/530/530/280/520/480/471/26
NephrolithiasisRenal and urinary disorders0/530/530/530/280/520/480/471/26
Anal fistulaGastrointestinal disorders0/530/531/531/280/520/480/470/26
Perirectal abscessInfections and infestations0/530/530/531/280/520/480/470/26
ParaesthesiaNervous system disorders0/530/530/531/280/520/480/470/26
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/530/530/531/280/520/480/470/26
Most frequent other events
Showing 10 of 21
Most frequent other events
EventDouble-Blind Andecaliximab 150 mg Every 2 Weeks (Q2W)Double-Blind Andecaliximab 150 mg Weekly (QW)Double-Blind Andecaliximab 300 mg WeeklyDouble-Blind PlaceboOpen-Label Andecaliximab QW From Andecaliximab 150 mg Q2WOpen-Label Andecaliximab QW From Andecaliximab 150 mg QWOpen-Label Andecaliximab QW From Andecaliximab 300 mg QWOpen-Label Andecaliximab QW From Placebo
Crohn's diseaseGastrointestinal disorders1/531/532/532/286/5210/484/475/26
NauseaGastrointestinal disorders3/531/537/535/283/524/481/472/26
PyrexiaGeneral disorders1/533/530/534/282/521/482/472/26
Abdominal painGastrointestinal disorders1/537/534/533/287/521/483/471/26
AnaemiaBlood and lymphatic system disorders0/532/536/530/281/521/481/471/26
FatigueGeneral disorders6/530/535/531/281/521/480/470/26
DizzinessNervous system disorders0/535/532/530/280/520/481/470/26
HeadacheNervous system disorders0/534/535/531/282/521/481/470/26
NasopharyngitisInfections and infestations2/531/534/530/284/523/484/471/26
Clostridium difficile infectionInfections and infestations0/531/530/530/280/520/480/472/26

Baseline characteristics

Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Andecaliximab 150 mg Every 2 WeeksAndecaliximab 150 mg WeeklyAndecaliximab 300 mg WeeklyPlaceboTotal
Mean38 ± 12.839 ± 13.542 ± 11.738 ± 13.539 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Andecaliximab 150 mg Every 2 WeeksAndecaliximab 150 mg WeeklyAndecaliximab 300 mg WeeklyPlaceboTotal
Female2528221590
Male2825311397
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Andecaliximab 150 mg Every 2 WeeksAndecaliximab 150 mg WeeklyAndecaliximab 300 mg WeeklyPlaceboTotal
Race — Asian11013
Race — Black or African American343111
Race — White48424822160
Race — Other10135
Race — Not Permitted06118
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Andecaliximab 150 mg Every 2 WeeksAndecaliximab 150 mg WeeklyAndecaliximab 300 mg WeeklyPlaceboTotal
Ethnicity — Hispanic or Latino11518
Ethnicity — Not Hispanic or Latino52464726171
Ethnicity — Not Permitted06118
Region of Enrollment
Region of Enrollment(Participants)Andecaliximab 150 mg Every 2 WeeksAndecaliximab 150 mg WeeklyAndecaliximab 300 mg WeeklyPlaceboTotal
Hungary21025
United States29283017104
Czechia12115
United Kingdom22206
Spain30205
New Zealand41005
Canada31004
Poland356216
Italy00112
South Africa00213
Australia32319
France06118
Germany355215
08

Study locations

74 sites
  • Digestive Health Specialists of The Southeast
    Dothan, Alabama, United States
  • Mayo Clinic
    Scottsdale, Arizona, United States
  • Cedars Sinai Medical Center
    Los Angeles, California, United States
  • South Denver Gastroenterology
    Lone Tree, Colorado, United States
  • University of Miami
    Miami, Florida, United States
  • Gastroenterology Group Of Naples
    Naples, Florida, United States
  • Gastroenterology Associates Of Central Georgia, LLC
    Macon, Georgia, United States
  • Medical Diagnostic Center (MDC)-Indiana University (IU) Health University Hospital
    Indianapolis, Indiana, United States
  • Iowa Digestive Disease Center
    Clive, Iowa, United States
  • Cotton-O'Neil Clinical Research Center, Digestive Health
    Topeka, Kansas, United States
  • Delta Research Partners
    Monroe, Louisiana, United States
  • Louisiana Research Center
    Shreveport, Louisiana, United States
  • University of Michigan
    Ann Arbor, Michigan, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota, United States
  • Washington University School of Medicine
    Saint Louis, Missouri, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire, United States
  • AGA Clinical Research Associates, LLC
    Egg Harbor Township, New Jersey, United States
  • Columbia University Medical Center/ New York Presbyterian
    New York, New York, United States
  • Premier Medical Group Of The Hudson Valley
    Poughkeepsie, New York, United States
  • Mayo Clinic Rochester
    Rochester, New York, United States
  • Asheville Gastroenterology Associates
    Asheville, North Carolina, United States
  • Consultants For Clinical Research
    Cincinnati, Ohio, United States
  • Great Lakes Gastroenterology
    Mentor, Ohio, United States
  • Gastro One
    Germantown, Tennessee, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee, United States
  • Texas Clinical Research Institute
    Arlington, Texas, United States
  • Ertan Digestive Disease Center of Excellence, UTH/MH-TMC
    Houston, Texas, United States
  • Gastroenterology Research of San Antonio
    San Antonio, Texas, United States
  • Gastroenterology Associates Of Tidewater
    Chesapeake, Virginia, United States
  • Digestive and Liver Disease Specialists
    Norfolk, Virginia, United States
  • Mcguire Dvamc
    Richmond, Virginia, United States
  • University of Washington Medical Center
    Seattle, Washington, United States
  • Concord Repatriation General Hospital
    Concord, New South Wales, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia, Australia
  • Footscray Hospital
    Footscray, Victoria, Australia
  • Gastroenterology/Colorectal Medicine & Genetics
    Melbourne, Victoria, Australia
  • Percuro Clinical Research Ltd.
    Victoria, British Columbia, Canada
  • Percuro Clinical Research Ltd.
    Victoria, Canada
  • Hepato-Gastroenterologie Hk S.R.O.
    Hradec Kralove 2, Czechia
  • Ibd Clinical And Research Centre-Iscare Ivf
    Praha 7, Czechia
  • Hopital Beaujon
    Clichy Cedex, France
  • CHRU de Lille
    Lille, France
  • Chu Hotel Dieu-Chu De Nantes
    Nantes, France
  • CHU de Saint Etienne - Hopital Nord
    Saint Priest en Jarez, France
  • Universitatsklinikum Schleswig-Holstein
    Kiel, Germany
  • Eugastro Gmbh
    Leipzig, Germany
  • Klinikum der Universitat Munchen
    Muenchen, Germany
  • Rethy Pal Hospital-Clinic Bekescsaba
    Bekescsaba, Hungary
  • Tolna Megye Balassa Janos Korhaz
    Beri Balogh Adam, Hungary
  • Pannonia Maganorvosi Centrum Kft
    Budapest, Hungary
  • Debreceni Egyeterm Orvos es Egeszsegtudomanyi Centrum
    Debrecen, Hungary
  • Universita Campus Biomedico
    Roma, Italy
  • Humanitas Research Hospital
    Rozzano, Italy
  • Christchurch Hospital
    Christchurch, New Zealand
  • Southern District Health Board
    Dunedin, New Zealand
  • Capital and Coast District Health board-Wellington hospital
    Wellington, New Zealand
  • The Medical University of Bialystok Clinical
    Bialystok, Poland
  • Gastromed
    Lublin, Poland
  • Ai Centrum Medyczne
    Poznan, Poland
  • CRC Sp. z o.o.
    Poznan, Poland
  • Endoskopia SP. z.o.o.
    Sopot, Poland
  • Centralny Szpital Kliniczny MSWiA
    Warszawa, Poland
  • Lexmedica
    Wroclaw, Poland
  • Panorama Mediclinic Pvt Hospital
    Panorama, Cape Town, South Africa
  • Parklands Medical Centre
    Durban, South Africa
  • Hospital Universitari de Bellvitge
    Barcelona, Spain
  • Hospital Universitario de Fuenlabrada
    Fuenlabrada, Spain
  • Hospital Ramon y Cajal
    Madrid, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, Spain
  • Norfolk and Norwich University Hospital Nhs Foundation Trust
    Norwich, Norfolk, United Kingdom
  • Cambridge University Hospitals NHS Foundation Trust
    Cambridge, United Kingdom
  • Oxford University Hospitals NHS Trust
    Oxford, United Kingdom
09

References and documents

Publications

  • Schreiber S, Siegel CA, Friedenberg KA, Younes ZH, Seidler U, Bhandari BR, Wang K, Wendt E, McKevitt M, Zhao S, Sundy JS, Lee SD, Loftus EV. A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease. J Crohns Colitis. 2018 Aug 29;12(9):1014-1020. doi: 10.1093/ecco-jcc/jjy070. PubMed 29846530 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Nov 2016, 19 months.

Results were first posted in Mar 2019, 2 years 3 months after primary completion. A results delay was requested in Feb 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2015
First posted
Apr 1, 2015
StartActual
Apr 30, 2015
Primary completionActual
Nov 30, 2016
CompletionActual
Dec 22, 2016
Results delay requested
Feb 23, 2017
Results first posted
Mar 28, 2019
Last update
Apr 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02405442
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 1, 2015
Start date
Apr 30, 2015
Primary completion
Nov 30, 2016
Completion
Dec 22, 2016
Results posted
Mar 28, 2019
Last update
Apr 23, 2019

Study contacts

Gilead Study Team
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andecaliximab

Start the discussion